[HTML][HTML] Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons

JR Muñoz-Montaño, FJ Moreno, J Avila, J Dı́az-Nido - FEBS letters, 1997 - Elsevier
JR Muñoz-Montaño, FJ Moreno, J Avila, J Dı́az-Nido
FEBS letters, 1997Elsevier
In Alzheimer's disease, tau protein becomes hyperphosporylated, which can contribute to
neuronal degeneration. However, the implicated protein kinases are still unknown. Now we
report that lithium (an inhibitor of glycogen synthase kinase-3) causes tau
dephosphorylation at the sites recognized by antibodies Tau-1 and PHF-1 both in cultured
neurons and in vivo in rat brain. This is consistent with a major role for glycogen synthase
kinase-3 in modifying proline-directed sites on tau protein within living neurons under …
In Alzheimer's disease, tau protein becomes hyperphosporylated, which can contribute to neuronal degeneration. However, the implicated protein kinases are still unknown. Now we report that lithium (an inhibitor of glycogen synthase kinase-3) causes tau dephosphorylation at the sites recognized by antibodies Tau-1 and PHF-1 both in cultured neurons and in vivo in rat brain. This is consistent with a major role for glycogen synthase kinase-3 in modifying proline-directed sites on tau protein within living neurons under physiological conditions. Lithium also blocks the Alzheimer's disease-like proline-directed hyperphosphorylation of tau protein which is observed in neurons treated with a phosphatase inhibitor. These data raise the possibility of using lithium to prevent tau hyperphosphorylation in Alzheimer's disease.
Elsevier